drugset / Trial / NCT00837863

Study of Weekly ALTU-238 Compared With Daily Nutropin AQ in Prepubertal Children With Growth Hormone Deficiency

NCT00837863

Phase 2 Unknown 36 enrolled Altus Pharmaceuticals
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of the study is to evaluate the safety and effectiveness of ALTU-238 in the treatment of children with growth hormone deficiency who have not yet reached puberty who lack the normal ability to make growth hormone themselves. This study will also test if ALTU-238 works as a weekly treatment.

Timeline

Start
2009-03
Primary completion
2010-09
Completion

Drugs

EvaluationDrugModalityDoseRoute
Comparator Somatropin Protein / enzyme biologic 0.043 mg/kg
Comparator Somatropin Protein / enzyme biologic 0.3 mg/kg
Comparator Somatropin Protein / enzyme biologic 0.6 mg/kg
Comparator Somatropin Protein / enzyme biologic 0.9 mg/kg

Indications